TauroLock™-U25.000

• hemodialysis
• oncology
• parenteral nutrition
• intensive care 

• 1.35 % taurolidine: broad antimicrobial activity against bacteria and fungi without generating resistance
• 4 % citrate: anticoagulant to maintain patency
• 25,000 units urokinase: thrombolytic to break up blood clotting

• prevention of biofilm
• prevention of occlusion/thrombosis
• prevention of infection

• single dose: 5 ml vials (5 per box)
• store between 15 and 25 °C (do not freeze) 

Clinical study 2021

“... the use of systematic locking with [TauroLock™-U25.000] in the long interdialytic period significantly reduces the number of replacements due to dysfunction, increasing primary patency rates with no additional financial cost.” 

Fontseré et al. Nefrologia (Engl Ed) 2021. DOI: 10.1016/j.nefro.2021.02.004 

Clinical study 2021

“Prophylactic use of [TauroLock™-U25.000] is highly effective in reducing the number of thrombotic catheter dysfunctions in catheters with a history of recurring dysfunction.”  

Bonkain et al. PLoS One 2021. DOI: 10.1371/journal.pone.0251793

Clinical study 2018

“... use of taurolidine-based catheter lock solutions containing heparin [TauroLock™-HEP500] and urokinase [TauroLock™-U25.000] significantly reduced complications related to tunneled hemodialysis catheters when compared to four percent citrate solution and was overall more cost-efficient.” 

Winnicki et al. Kidney Int 2018. DOI: 10.1016/j.kint.2017.06.026

Clinical study 2018

“[Taurolock™-U25.000] is a safe and effective tunneled dialysis catheter lock solution, with a low rate of catheter exchange.” 

Al-Ali et al. Nephrol Dial Transplant 2018. DOI: 10.1093/ndt/gfx187